Amid scrutiny over Robert F. Kennedy Jr.'s pledge to divest his financial stake in vaccine lawsuits to his family, legal ...

Truist has recently reduced Merck & Co Inc (MRK) stock to Hold rating, as announced on January 8, 2025, according to Finviz. Earlier, on December 20, 2024, BMO Capital Markets had reduced the stock ...

Merck shares are down more than 20% over the past 12 months after trouble with sales of its Gardasil vaccine in China ...

We recently published an article titled Jim Cramer’s Game Plan: 15 Stocks in Focus. In this article, we are going to take a ...

The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension functional class two ...

In a report released on January 30, Daina Graybosch from Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research ...

We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Amazon and Google parent Alphabet are set to report earnings, along with other tech companies including AI darling Palantir, and chipmaker Advanced Micro Devices. Pharmaceutical firms Novo Nordisk, ...

Robert F. Kennedy Jr., Trump's pick to head the Department of Health and Human Services, faces scrutiny for fees he may earn from lawsuits against Merck.

With a volume of 4,802,873, the price of MRK is down -0.11% at $98.84. RSI indicators hint that the underlying stock is currently neutral between overbought and oversold. Next earnings are expected to ...

Robert F. Kennedy Jr. also disclosed that he had reached at least one settlement agreement with a company or individual that ...

Merck is ending a Phase 3 trial of Winrevair early so all PAH patients in HYPERION can start active treatment with the drug ...